TW202444423A - 抗cdh6抗體-藥物結合物與vegf抑制劑之組合 - Google Patents
抗cdh6抗體-藥物結合物與vegf抑制劑之組合 Download PDFInfo
- Publication number
- TW202444423A TW202444423A TW113109250A TW113109250A TW202444423A TW 202444423 A TW202444423 A TW 202444423A TW 113109250 A TW113109250 A TW 113109250A TW 113109250 A TW113109250 A TW 113109250A TW 202444423 A TW202444423 A TW 202444423A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- cancer
- cdh6
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-039600 | 2023-03-14 | ||
| JP2023039600 | 2023-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202444423A true TW202444423A (zh) | 2024-11-16 |
Family
ID=92755258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113109250A TW202444423A (zh) | 2023-03-14 | 2024-03-13 | 抗cdh6抗體-藥物結合物與vegf抑制劑之組合 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPWO2024190815A1 (enExample) |
| KR (1) | KR20250170141A (enExample) |
| CN (1) | CN120813389A (enExample) |
| AU (1) | AU2024236246A1 (enExample) |
| MX (1) | MX2025010805A (enExample) |
| TW (1) | TW202444423A (enExample) |
| WO (1) | WO2024190815A1 (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| EP2001358B1 (en) | 2006-03-27 | 2016-07-13 | University Of Maryland, Baltimore | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| EP2812442B9 (en) | 2012-02-10 | 2023-02-15 | University of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| CN104755494B (zh) | 2012-10-11 | 2018-09-07 | 第一三共株式会社 | 抗体-药物偶联物 |
| HRP20190056T1 (hr) | 2013-12-25 | 2019-02-22 | Daiichi Sankyo Company, Limited | Konjugat anti-trop2 antitijelo-lijek |
| SMT202500030T1 (it) | 2014-01-31 | 2025-03-12 | Daiichi Sankyo Co Ltd | Coniugato anticorpo anti-her2-farmaco |
| DK3129063T3 (da) | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
| BR112019012847A2 (pt) | 2017-01-17 | 2019-12-10 | Daiichi Sankyo Co Ltd | anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor. |
| TW202532101A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體-藥物結合物及其用途 |
| US11945882B2 (en) | 2017-08-31 | 2024-04-02 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
| EP3834843A4 (en) * | 2018-08-06 | 2022-05-11 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR |
| EA202191641A1 (ru) * | 2018-12-11 | 2021-09-13 | Дайити Санкио Компани, Лимитед | Комбинация конъюгата антитело-лекарственное средство с ингибитором parp |
| BR112021011894A2 (pt) * | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| KR20220152318A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4444360A1 (en) | 2021-12-10 | 2024-10-16 | Multitude Therapeutics Inc. | Anti-cdh6 antibodies and antibody-drug conjugates thereof |
| WO2023102875A1 (en) | 2021-12-10 | 2023-06-15 | Multitude Therapeutics Inc. | Anti-cdh6 antibody drug conjugate |
-
2024
- 2024-03-13 JP JP2025506895A patent/JPWO2024190815A1/ja active Pending
- 2024-03-13 WO PCT/JP2024/009716 patent/WO2024190815A1/ja active Pending
- 2024-03-13 KR KR1020257033997A patent/KR20250170141A/ko active Pending
- 2024-03-13 CN CN202480018403.0A patent/CN120813389A/zh active Pending
- 2024-03-13 TW TW113109250A patent/TW202444423A/zh unknown
- 2024-03-13 AU AU2024236246A patent/AU2024236246A1/en active Pending
-
2025
- 2025-09-12 MX MX2025010805A patent/MX2025010805A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025010805A (es) | 2025-11-03 |
| CN120813389A (zh) | 2025-10-17 |
| JPWO2024190815A1 (enExample) | 2024-09-19 |
| AU2024236246A1 (en) | 2025-10-30 |
| WO2024190815A1 (ja) | 2024-09-19 |
| KR20250170141A (ko) | 2025-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101941758B1 (ko) | 항 trop2 항체-약물 컨쥬게이트 | |
| JP7458981B2 (ja) | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP7769032B2 (ja) | 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| AU2019396895A1 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| US20230414778A1 (en) | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | |
| KR20230041023A (ko) | 항체-약물 콘주게이트의 제조 방법 | |
| TW202216207A (zh) | 抗體-藥物結合物及cdk9抑制劑之組合 | |
| JP2025517656A (ja) | 腫瘍抗原に特異的である抗体と、cd47阻害剤との組合せ | |
| TW202444423A (zh) | 抗cdh6抗體-藥物結合物與vegf抑制劑之組合 | |
| TW202444427A (zh) | 抗CDH6抗體-藥物結合物與HIF-2α抑制劑之組合 | |
| TW202446421A (zh) | 抗b7-h3抗體-藥物結合物與atr抑制劑或atm抑制劑之組合 | |
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| HK40093327A (en) | Combination of antibody-drug conjugate with anti-sirpalpha antibody | |
| TW202216214A (zh) | 抗her2抗體-藥物結合物與her二聚化抑制劑的組合 | |
| HK40064358A (en) | Combination of antibody-drug conjugate with parp inhibitor | |
| HK40045208A (en) | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |